Claims substantiation starts before the marketing copy

A small wording change can create a different evidence burden

‘Supports sleep’ and ‘reduces insomnia’ may sound adjacent in a workshop. They are not the same claim. One may describe general support; the other names a condition and implies a therapeutic effect. ‘Clinically tested’ says something different from ‘clinically proven.’ A claim about an ingredient is not automatically a claim about the finished product.

Substantiation therefore cannot begin with a generic search for favourable studies. It begins by freezing the wording, identifying what a reasonable consumer is likely to understand, and specifying the product, dose, population, outcome and use conditions behind it.

A structured scientific literature review can map the evidence behind a proposed claim before specialist legal or regulatory review.

Build a claim-to-evidence map

A practical map has two sides. On the claim side: the exact wording, implied meaning, target audience, product formulation, dose, timeframe and channels where the claim will appear. On the evidence side: study population, intervention, comparator, outcomes, duration, design quality, statistical and practical relevance, and independence.

The map reveals common mismatches quickly. Evidence in a different population may be interesting but indirect. An ingredient study at twice the marketed dose may not support the finished-product claim. A statistically significant change in a laboratory marker may not justify a consumer-facing benefit. A study designed by the sponsor is not automatically invalid, but independence and selective reporting become part of the appraisal.

‘Competent and reliable’ is not a magic phrase

US guidance for health products and dietary supplements emphasises the amount, type and quality of evidence in relation to the claim. European rules for cosmetic claims set common criteria that include evidential support, truthfulness and honesty. The details differ by category and jurisdiction, which is why a research brief should inform qualified legal or regulatory review rather than impersonate it.

The shared principle is fit. Strong methods applied to the wrong product, endpoint or population do not create strong substantiation. Nor does one favourable study erase a larger inconsistent literature.

Look for the whole evidence pattern

A useful review records favourable, null and adverse findings. It examines whether results repeat across teams and methods, whether outcomes were pre-specified, whether attrition or multiple testing could distort the result, and whether the effect is large enough to matter in use.

Where several studies exist, do not count positive papers. Compare their directness and quality. Ten weak, indirect studies do not necessarily outweigh one rigorous trial that directly tests the marketed use. Equally, a single null study may not settle a heterogeneous question. The job is calibration, not scorekeeping.

Use research before copy approval and before study design

There are two useful moments for evidence synthesis. The first is before approving copy: test whether the current evidence supports the proposed wording and identify safer, more precise alternatives. The second is before commissioning research: find the exact gap so a new study answers the claim instead of generating another adjacent result.

This can save money in both directions. It prevents an expensive study built around an outcome consumers will never see, and it prevents marketing from stretching a defensible finding into a stronger claim the study did not test.

A decision-ready output

The final brief should list each proposed claim, the best supporting evidence, material contrary evidence, directness to the finished product, key limitations, and a calibrated status such as supported, supportable with narrower wording, uncertain, or not supported on the reviewed evidence.

Those labels are research judgements, not legal clearance. Their value is that everyone sees the same chain between wording and evidence before the claim reaches the market.